ArticleJournal of bioethical inquiry2026
Evolving Paradigms in China's Human Genetic Resource Regulation : From Biopiracy Prevention to Bridging National Interests and Global Collaboration.
Article in Journal of bioethical inquiry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While existing literature often portrays China's human genetic resource (HGR) regulations as primarily restrictive, this report demonstrates their evolution towards a more sophisticated and balanced framework. First, China's transition from addressing biopiracy to incorporating HGR management into national security frameworks reflects a reconceptualization of genetic resources as strategic assets. Second, regulatory changes since 2023 show increasing flexibility in international collaboration, particularly in clinical trials, whilst maintaining protective measures. Third, regarding ethical management, the absence of clear legal distinctions between HGRs at the natural state and processed cellular products may negatively affect biotech industry development, while donors' property rights over their genetic resources remain unsettled. These findings demonstrate how China has continuously refined its HGR regulatory framework to protect national interests whilst advancing innovation and international scientific cooperation.
Indexed as
Identifiers
41925993What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.